Foundry Partners LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 187,165 shares of the company’s stock, valued at approximately $22,110,000. Johnson & Johnson comprises approximately 1.2% of Foundry Partners LLC’s holdings, making the stock its 7th largest position.

Other institutional investors also recently added to or reduced their stakes in the company. Americafirst Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC bought a new position in Johnson & Johnson during the second quarter valued at about $103,000. Lenox Wealth Management Inc. increased its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. increased its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. bought a new position in Johnson & Johnson during the second quarter valued at about $127,000. Institutional investors own 64.13% of the company’s stock.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.7333% during trading on Wednesday, hitting $111.6552. 2,220,099 shares of the company’s stock were exchanged. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The firm has a market capitalization of $303.76 billion, a PE ratio of 19.5989 and a beta of 0.75. The stock’s 50 day moving average is $115.97 and its 200 day moving average is $118.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The business had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. During the same period in the previous year, the firm earned $1.49 EPS. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post $6.72 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be issued a $0.80 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s payout ratio is presently 56.64%.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/187165-shares-in-johnson-johnson-jnj-acquired-by-foundry-partners-llc.html.

A number of brokerages have recently commented on JNJ. Credit Suisse Group AG reaffirmed a “neutral” rating and issued a $123.00 target price on shares of Johnson & Johnson in a report on Monday, September 19th. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price for the company. in a report on Tuesday, November 1st. Bank of America Corp. reaffirmed a “hold” rating and issued a $126.00 target price on shares of Johnson & Johnson in a report on Monday. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price for the company in a report on Friday, August 5th. Finally, Jefferies Group upped their target price on shares of Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a report on Thursday, August 4th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $121.03.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the company’s stock in a transaction that occurred on Friday, October 21st. The shares were acquired at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the acquisition, the director now directly owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.11% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.